Bioequivalence Study of Klaribact 125mg/5ml, Suspension
Status:
Completed
Trial end date:
2013-10-25
Target enrollment:
Participant gender:
Summary
A two way crossover BE study will be performed to evaluate the comparative bioavailability of
Klaribact (Clarithromycin 125 mg/5ml) suspension (Merck Pvt. Ltd, Pakistan) with Klaricid
(Clarithromycin 125mg/5ml) suspension (Abbot Laboratories Pakistan Limited) at the clinical
site (CBSCR), Karachi Pakistan.
Phase:
N/A
Details
Lead Sponsor:
University of Karachi
Collaborators:
Center for Bioequivalence Studies and Clinical Research (CBSCR), HEJ Research Institute of chemistry, University of Karachi Merck (Pvt.) Limited, Pakistan